ReviewAAPS PharmSciTech2026
Smart Surface-Engineered Mesoporous Silica Nanoparticles for Brain Tumor Therapy: Overcoming the Blood-Brain Barrier for Advanced Theranostics.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumors, particularly glioblastoma multiforme (GBM), remain among the most lethal forms of cancer due to their aggressive nature and the formidable challenge posed by the blood-brain barrier (BBB), which restricts the delivery of therapeutic agents. Conventional treatment modalities, including surgery, radiotherapy, and chemotherapy, often fail to achieve effective and targeted therapy without inducing systemic toxicity or damaging healthy brain tissue. In recent years, mesoporous silica nanoparticles (MSNs)have emerged as a versatile platform for targeted brain tumor therapy because of their high surface area, tunable pore structure, biocompatibility, and ease of surface functionalization. This review critically examines advanced surface functionalization strategies, including chemical functionalization (amine, thiol, carboxyl groups), ligand conjugation (antibodies, aptamers, peptides), and polymeric coatings (PEG, chitosan, PLGA) that enhance BBB penetration, facilitate tumor-specific targeting, and enable stimuli-responsive drug release (different types of exogenous and endogenous). We also explore the interactions of these modifications with key signaling pathways (e.g., Wnt/β-catenin, PDGF-B, TGF-β) that regulate BBB integrity and glioma progression. Special emphasis is placed on how surface-engineered MSNs can improve site-specific drug delivery, increase therapeutic accumulation in brain tumor tissue, and minimize off-target toxicity. Despite the considerable promise demonstrated by these techniques in preclinical glioma models, obstacles such as scalable synthesis, regulatory compliance, and long-term biosafety must be addressed to facilitate clinical translation. This review focuses specifically on brain tumor targeting via functionalized MSNs and provides mechanistic insights while highlighting emerging strategies to advance MSNs as next-generation therapeutics for brain tumor treatment.
Indexed as
Identifiers
42736498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.